Robert Dickey - Aug 15, 2025 Form 4 Insider Report for Vyome Holdings, Inc (HIND)

Role: Chief Financial Officer
Signature: /s/ Robert Dickey
Stock symbol: HIND
Transactions as of: Aug 15, 2025
Transactions value $: $0
Form type: 4
Date filed: 9/11/2025, 09:21 PM
Previous filing: Aug 17, 2023
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Dickey Robert IV	Chief Financial Officer	HARVARD SQUARE,, ONE MIFFLIN PLACE, SUITE 400, CAMBRIDGE	/s/ Robert Dickey	2025-09-11	0001466862

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HIND	Common Stock	Award		+762			762	Aug 15, 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

Content

Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.